<DOC>
	<DOCNO>NCT00739115</DOCNO>
	<brief_summary>The purpose study evaluate safety utility use heliox gas combination nasal CPAP premature infant . The investigator hypothesize use heliox gas combination nasal CPAP result decrease early nasal CPAP failure require intubation mechanical ventilation .</brief_summary>
	<brief_title>The Use Heliox Via Nasal CPAP Prevent Early CPAP Failure Premature Infants : A Feasibility Study</brief_title>
	<detailed_description>Introduction : In recent year increase use nasal continuous positive airway pressure ( nCPAP ) management premature infant respiratory distress syndrome ( RDS ) . The use early nCPAP eliminates need endotracheal intubation mechanical ventilation , associated morbidity . In clinical practice significant number extremely low birth weight ( ELBW ) infant RDS fail nCPAP therapy within first 72 hour life require rescue endotracheal intubation . The clinical factor result nCPAP failure hypoxemia , hypoventilation , muscular fatigue and/or apnea . Helium biologically inert gas use medicine carrier oxygen . Heliox ( mixture helium oxygen ) use safely neonates decade use consistently show improve oxygenation , enhance ventilation decrease work breathing . Prior study use heliox management premature infant RDS show clear therapeutic benefit . The use heliox deliver via nCPAP device ( Hx-nCPAP ) recently report infant bronchiolitis . Given prior success heliox management RDS combine recent advent Hx-nCPAP intend investigate utility Hx-nCPAP reduce incidence early nCPAP failure ELBW infant RDS . Research design : Prospective , open-label , randomize , pilot study compare conventional nCPAP Hx-nCPAP management ELBW infant treat nCPAP RDS . Methods : All spontaneously breathe infant bear &lt; 30 wks estimate gestational age ( EGA ) admit NICU KMCWC diagnosis RDS nCPAP since birth eligible enrollment . Volunteer Infants randomly assign conventional nCPAP Hx-nCPAP group . Hx-nCPAP provide study group infant first 72 hour life . Primary secondary outcome measure compare heliox group control group determine Hx-nCPAP result decrease incidence early nCPAP failure and/or improve clinical outcome compare conventional nCPAP .</detailed_description>
	<mesh_term>Respiratory Distress Syndrome , Newborn</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Adult</mesh_term>
	<criteria>Gestational age &lt; 33 week Receiving CPAP time delivery Cyanotic congenital heart disease Congenital malformation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>12 Hours</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Respiratory</keyword>
	<keyword>Distress</keyword>
	<keyword>Prematurity</keyword>
	<keyword>Heliox</keyword>
	<keyword>CPAP</keyword>
</DOC>